Profile of gantenerumab and its potential in the treatment of Alzheimer's disease.
Profile of gantenerumab and its potential in the treatment of Alzheimer's disease.
复制标题
DOI：
10.2147/dddt.s53401
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Nisticò R
中科院分区：
文献类型：
--
作者：
Novakovic D;Feligioni M;Scaccianoce S;Caruso A;Piccinin S;Schepisi C;Errico F;Mercuri NB;Nicoletti F;Nisticò R
阿尔茨海默病的特点是认知能力逐渐下降，伴随着日常生活活动的恶化和整个疾病过程中的行为障碍。据估计，全世界有2700万人患有阿尔茨海默病。预计到2030年，全球将有6300万人感染这种疾病，到2050年将有1.14亿人感染这种疾病。目前的阿尔茨海默病药物可以缓解症状一段时间，但不能减缓疾病的进展。事实上，所有目前可用的治疗方法，如胆碱酯酶抑制剂（多奈哌齐、加兰他明、利瓦斯替明），主要被认为是对症治疗，尽管最近的数据也表明可能的疾病改善作用。Gantenerumab是一种研究性的全人抗淀粉样蛋白β单克隆抗体，具有结合和去除大脑中β淀粉样蛋白斑块的高能力。该化合物目前正在进行II期和III期临床试验，代表了一种有希望的药物，具有改善阿尔茨海默病的潜力。在这里，我们提出了从临床前研究到人体临床试验的更纳单抗的概述。
Alzheimer’s disease, which is characterized by gradual cognitive decline associated with deterioration of daily living activities and behavioral disturbances throughout the course of the disease, is estimated to affect 27 million people around the world. It is expected that the illness will affect about 63 million people by 2030, and 114 million by 2050, worldwide. Current Alzheimer’s disease medications may ease symptoms for a time but are not capable of slowing down disease progression. Indeed, all currently available therapies, such as cholinesterase inhibitors (donepezil, galantamine, rivastigmine), are primarily considered symptomatic therapies, although recent data also suggest possible disease-modifying effects. Gantenerumab is an investigational fully human anti-amyloid beta monoclonal antibody with a high capacity to bind and remove beta-amyloid plaques in the brain. This compound, currently undergoing Phase II and III clinical trials represents a promising agent with a disease-modifying potential in Alzheimer’s disease. Here, we present an overview of gantenerumab ranging from preclinical studies to human clinical trials.